Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer

Tsang, Roger Y.; Finn, Richard S.

doi:10.1038/bjc.2011.516

Cited by 76 publications

(47 citation statements)

References 71 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies were done from basic mechanism of HER family for cell proliferation and oncogenesis, HER2 overexpression or amplification in various solid tumors to clinical treatment of breast cancer, gastroesophageal cancer by trastuzumab in many recent reviews [1][2][3][4][5][6][7][8].…”

Section: Introduction Egfr and Her2 Family With Signal Pathway And Camentioning

confidence: 99%

HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment

Zhou¹,

Hick²

2013

Oncogene and Cancer - From Bench to Clinic

View full text Add to dashboard Cite

Section: Introduction Egfr and Her2 Family With Signal Pathway And Camentioning

confidence: 99%

HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment

Zhou¹,

Hick²

2013

Oncogene and Cancer - From Bench to Clinic

View full text Add to dashboard Cite

“…Recent studies indicate that HER2-positive breast cancer is biologically heterogeneous (22). Promising novel anti-HER2 agents are currently being developed and may ultimately prove to be safe and effective for patients with de novo or acquired resistant tumors (23)(24)(25). In addition, the safety and efficacy of T-DM1 in patients with early breast cancer are being evaluated in ongoing studies (Table 2).…”

Section: Discussionmentioning

confidence: 99%

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Amiri‐Kordestani

Blumenthal

et al. 2014

Clinical Cancer Research

284

173

View full text Add to dashboard Cite

On February 22, 2013, the FDA licensed ado-trastuzumab emtansine (Kadcyla; Genentech, Inc.) for use as a single agent for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. The clinical basis for licensure was a phase III trial in 991 patients with HER2-positive MBC that randomly allocated patients to receive ado-trastuzumab emtansine (n ¼ 495) or lapatinib in combination with capecitabine (n ¼ 496). The coprimary endpoints were progression-free survival (PFS) based on tumor assessments by an independent review committee and overall survival (OS). Statistically significant improvements in PFS and OS were observed in patients receiving ado-trastuzumab emtansine compared with patients receiving lapatinib plus capecitabine [difference in PFS medians of 3.2 months, HR, 0.65 (95% confidence interval, CI, 0.55-0.77), P < 0.0001 and difference in OS medians of 5.8 months, HR, 0.68 (95% CI, 0.55-0.85), P ¼ 0.0006]. The most common adverse reactions in patients receiving adotrastuzumab emtansine were fatigue, nausea, musculoskeletal pain, thrombocytopenia, headache, increased aminotransferase levels, and constipation. Other significant adverse reactions included hepatobiliary disorders and left ventricular dysfunction. Given the PFS and OS results, the benefit-risk profile was considered favorable. Clin Cancer Res; 20(17); 4436-41. Ó2014 AACR.

show abstract

“…A large fraction of these investigational combinational therapies aims for treating the various types of cancer. For instance, novel therapeutic strategies in HER2-positive metastatic breast cancer, beyond the established treatment with trastuzumab and chemotherapy, focus on circumventing frequently emerging primary and secondary resistance to trastuzumab therapy (80). Novel combinatorial compounds target the prevalent resistance mechanisms associated with trastuzumab therapy (81).…”

Section: Drug Combinationsmentioning

confidence: 99%

From protein interaction networks to novel therapeutic strategies

Jaeger

Aloy

2012

IUBMB Life

View full text Add to dashboard Cite

SummaryCellular mechanisms that sustain health or contribute to disease emerge mostly from the complex interplay among various molecular entities. To understand the underlying relationships between genotype, environment and phenotype, one has to consider the intricate and nonsequential interaction patterns formed between the different sets of cellular players. Biological networks capture a variety of molecular interactions and thus provide an excellent opportunity to consider physiological characteristics of individual molecules within their cellular context. In particular, the concept of network biology and its applications contributed largely to recent advances in biomedical research. In this review, we show (i) how biological networks, i.e., protein-protein interaction networks, facilitate the understanding of pathogenic mechanisms that trigger the onset and progression of diseases and (ii) how this knowledge can be translated into effective diagnostic and therapeutic strategies. In particular, we focus on the impact of network pharmacological concepts that go beyond the classical view on individual drugs and targets aiming for combinational therapies with improved clinical efficacy and reduced safety risks.2012 IUBMB IUBMB Life, 64(6): 529-537, 2012

show abstract

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer

Cited by 76 publications

References 71 publications

HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment

HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

From protein interaction networks to novel therapeutic strategies

Contact Info

Product

Resources

About